Download PDF
CC BY 4.0 · TH Open 2021; 05(01): e89-e103
DOI: 10.1055/s-0041-1723784
Original Article

Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients

Joseph M. Sweeney
1   Department Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York, United States
,
Mohammad Barouqa
2   Department of Pathology Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States
,
Gregory J. Krause
3   Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, United States
4   Institute of Aging Studies, Albert Einstein College of Medicine, Bronx, New York, United States
,
Jesus D. Gonzalez-Lugo
5   Division of Hematology, Department of Medical Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, United States
,
Shafia Rahman
5   Division of Hematology, Department of Medical Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, United States
,
Morayma Reyes Gil 
2   Department of Pathology Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States
› Author Affiliations Funding The authors would like to acknowledge the MSTP Training grant for partial support of J.M.S.'s effort (T32GM007288).
› Further Information
Also available at
   Permissions and Reprints

Abstract

The causes of coagulopathy associated with coronavirus disease 2019 (COVID-19) are poorly understood. We aimed to investigate the relationship between von Willebrand factor (VWF) biomarkers, intravascular hemolysis, coagulation, and organ damage in COVID-19 patients and study their association with disease severity and mortality. We conducted a retrospective study of 181 hospitalized COVID-19 patients randomly selected with balanced distribution of survivors and nonsurvivors. Patients who died had significantly lower ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity, significantly elevated lactate dehydrogenase levels, significantly increased shistocyte/RBC fragment counts, and significantly elevated VWF antigen and activity levels compared with patients discharged alive. These biomarkers correlate with markedly elevated D-dimers. Additionally, only 30% of patients who had an ADAMTS13 activity level of less than 43% on admission survived, yet 60% of patients survived who had an ADAMTS13 activity level of greater than 43% on admission. In conclusion, COVID-19 may present with low ADAMTS13 activity in a subset of hospitalized patients. Presence of schistocytes/RBC fragment and elevated D-dimer on admission may warrant a work-up for ADAMTS13 activity and VWF antigen and activity levels. These findings indicate the need for future investigation to study the relationship between endothelial and coagulation activation and the efficacy of treatments aimed at prevention and/or amelioration of microangiopathy in COVID-19.

Keywords

von Willebrand factor - ADAMTS13 - COVID-19 - schistocytes - coagulopathy

Authors' Contributions

M.R.G. designed and performed the research, analyzed and interpreted data, and wrote the manuscript. J.M.S. performed the research, analyzed and interpreted the data, and helped in manuscript writing. M.B. analyzed and interpreted the data and helped in manuscript writing. G.J.K. performed the research and analyzed the data. J.D.G. and S.R. performed chart review.


Note

M.R.G. and J.M.S. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.


Supplementary Material



Publication History

Received: 31 October 2020

Accepted: 29 December 2020

Article published online:
09 March 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507-513
    CrossrefPubMedGoogle Scholar
  • 2 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 3 Labò N, Ohnuki H, Tosato G. Vasculopathy and coagulopathy associated with SARS-CoV-2 infection. Cells 2020; 9 (07) E1583
    CrossrefPubMedGoogle Scholar
  • 4 Buja LM, Wolf DA, Zhao B. et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol 2020; 48: 107233
    CrossrefPubMedGoogle Scholar
  • 5 Deshpande C. Thromboembolic findings in COVID-19 autopsies: pulmonary thrombosis or embolism?. Ann Intern Med 2020; 173 (05) 394-395
    CrossrefPubMedGoogle Scholar
  • 6 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
    CrossrefPubMedGoogle Scholar
  • 7 Zhang L, Yan X, Fan Q. et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 18 (06) 1324-1329
    CrossrefPubMedGoogle Scholar
  • 8 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
    CrossrefPubMedGoogle Scholar
  • 9 Goshua G, Pine AB, Meizlish ML. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7 (08) e575-e582
    CrossrefPubMedGoogle Scholar
  • 10 Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 3 (08) 1702-1709
    CrossrefPubMedGoogle Scholar
  • 11 Escher R, Breakey N, Lämmle B. ADAMTS13 activity , von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients. Thromb Res 2020; 192: 174-175
    CrossrefPubMedGoogle Scholar
  • 12 Martinelli N, Montagnana M, Pizzolo F. et al. A relative ADAMTS13 activity deficiency supports the presence of a secondary microangiopathy in COVID 19. Thromb Res 2020; 193: 170-172
    CrossrefPubMedGoogle Scholar
  • 13 Huisman A, Beun R, Sikma M, Westerink J, Kusadasi N. Involvement of ADAMTS13 activity and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. Int J Lab Hematol 2020; 42 (05) e211-e212
    CrossrefPubMedGoogle Scholar
  • 14 Miller CH, Platt SJ, Daniele C, Kaczor D. Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2002; 88 (01) 56-59
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Lawrie AS, Hoser MJ, Savidge GF. Phast assessment of vWf:Ag multimeric distribution. Thromb Res 1990; 59 (02) 369-373
    CrossrefPubMedGoogle Scholar
  • 16 Hantaweepant C, Sasijareonrat N, Chutvanichkul B, Karaketklang K, Chinthammitr Y. Comparison between optical microscopy and the Sysmex XN-3000 for schistocyte determination in patients suspected of having schistocytosis. Health Sci Rep 2019; 3 (01) e138
    CrossrefPubMedGoogle Scholar
  • 17 Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk Adcock D. Differential sensitivity of von Willebrand factor (VWF) ‘activity’ assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost 2012; 10 (06) 1043-1054
    CrossrefPubMedGoogle Scholar
  • 18 Billett HH, Reyes-Gil M, Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120 (12) 1691-1699
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104 (01) 100-106
    CrossrefPubMedGoogle Scholar
  • 20 Ladikou EE, Sivaloganathan H, Milne KM. et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?. Clin Med (Lond) 2020; 20 (05) e178-e182
    CrossrefPubMedGoogle Scholar
  • 21 Liu F, Li L, Xu M. et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020; 127: 104370
    CrossrefPubMedGoogle Scholar
  • 22 Zhang J, Yu M, Tong S, Liu LY, Tang LV. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. J Clin Virol 2020; 127: 104392
    CrossrefPubMedGoogle Scholar
  • 23 Farkas P, Csuka D, Mikes B. et al. Complement activation, inflammation and relative ADAMTS13 activity deficiency in secondary thrombotic microangiopathies. Immunobiology 2017; 222 (02) 119-127
    CrossrefPubMedGoogle Scholar
  • 24 Kremer Hovinga JA, Zeerleder S, Kessler P. et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007; 5 (11) 2284-2290
    CrossrefPubMedGoogle Scholar
  • 25 Feys HB, Vandeputte N, Palla R. et al. Inactivation of ADAMTS13 activity by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8 (09) 2053-2062
    CrossrefPubMedGoogle Scholar
  • 26 Ono T, Mimuro J, Madoiwa S. et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13 activity) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107 (02) 528-534
    CrossrefPubMedGoogle Scholar
  • 27 Habe K, Wada H, Ito-Habe N. et al. Plasma ADAMTS13 activity, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res 2012; 129 (05) 598-602
    CrossrefPubMedGoogle Scholar
  • 28 Wada H, Mori Y, Shimura M. et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1998; 58 (03) 189-194
    CrossrefPubMedGoogle Scholar
  • 29 Smeets NJL, Fijnheer R, Sebastian S, De Mast Q. Secondary thrombotic microangiopathy with severely reduced ADAMTS13 activity in a patient with Capnocytophaga canimorsus sepsis: a case report. Transfusion 2018; 58 (10) 2426-2429
    CrossrefPubMedGoogle Scholar
  • 30 Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 activity deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015; 113 (04) 708-718
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost 2020; 18 (09) 2103-2109
    CrossrefPubMedGoogle Scholar
  • 32 Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017; 129 (21) 2836-2846
    CrossrefPubMedGoogle Scholar
  • 33 Lopes da Silva R. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther 2011; 4 (02) 51-59
    CrossrefPubMedGoogle Scholar
  • 34 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383 (02) 120-128
    CrossrefPubMedGoogle Scholar
  • 35 do Espírito Santo DA, Lemos ACB, Miranda CH. In vivo demonstration of microvascular thrombosis in severe COVID-19. J Thromb Thrombolysis 2020; 50 (04) 790-794
    CrossrefPubMedGoogle Scholar
  • 36 Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020; 8 (07) 681-686
    CrossrefPubMedGoogle Scholar
  • 37 Grosse C, Grosse A, Salzer HJF, Dünser MW, Motz R, Langer R. Analysis of cardiopulmonary findings in COVID-19 fatalities: high incidence of pulmonary artery thrombi and acute suppurative bronchopneumonia. Cardiovasc Pathol 2020; 49: 107263
    CrossrefPubMedGoogle Scholar
  • 38 Mackman N, Antoniak S, Wolberg AS, Kasthuri R, Key NS. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler Thromb Vasc Biol 2020; 40 (09) 2033-2044
    CrossrefPubMedGoogle Scholar
  • 39 Rapkiewicz AV, Mai X, Carsons SE. et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine 2020; 24: 100434
    CrossrefPubMedGoogle Scholar
  • 40 Schutte T, Thijs A, Smulders YM. Never ignore extremely elevated D-dimer levels: they are specific for serious illness. Neth J Med 2016; 74 (10) 443-448
    PubMedGoogle Scholar
  • 41 Mazzaccaro D, Giacomazzi F, Giannetta M. et al. Non-overt coagulopathy in non-ICU patients with mild to moderate COVID-19 pneumonia. J Clin Med 2020; 9 (06) E1781
    CrossrefPubMedGoogle Scholar
  • 42 Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res 2020; 192: 152-160
    CrossrefPubMedGoogle Scholar
  • 43 Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol 2020; 16 (10) 581-589
    CrossrefPubMedGoogle Scholar
  • 44 Yatabe T, Inoue S, Sakamoto S. et al. The anticoagulant treatment for sepsis induced disseminated intravascular coagulation; network meta-analysis. Thromb Res 2018; 171: 136-142
    CrossrefPubMedGoogle Scholar
  • 45 Okajima M, Takahashi Y, Kaji T, Ogawa N, Mouri H. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: four case reports. World J Clin Cases 2020; 8 (21) 5320-5325
    CrossrefPubMedGoogle Scholar
  • 46 Scully M, Cataland SR, Peyvandi F. et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380 (04) 335-346
    CrossrefPubMedGoogle Scholar
  • 47 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81 (01) 8-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Fischer JC, Zänker K, van Griensven M. et al. The role of passive immunization in the age of SARS-CoV-2: an update. Eur J Med Res 2020; 25 (01) 16
    CrossrefPubMedGoogle Scholar
  • 49 Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; 368: m1256
    CrossrefPubMedGoogle Scholar
  • 50 Valk SJ, Piechotta V, Chai KL. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev 2020; 5: CD013600
    PubMedGoogle Scholar
  • 51 Himmelfarb J, McMonagle E, Holbrook D, Hakim R. Increased susceptibility to erythrocyte C5b-9 deposition and complement-mediated lysis in chronic renal failure. Kidney Int 1999; 55 (02) 659-666
    CrossrefPubMedGoogle Scholar
  • 52 Diurno F, Numis FG, Porta G. et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 2020; 24 (07) 4040-4047
    PubMedGoogle Scholar
  • 53 Giudice V, Pagliano P, Vatrella A. et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol 2020; 11: 857
    CrossrefPubMedGoogle Scholar
  • 54 Laurence J, Mulvey JJ, Seshadri M. et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol 2020; 219: 108555
    CrossrefPubMedGoogle Scholar